Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 15/20 | 0.44 |
| ▸ | CASP6 | P55212 | 14/20 | 0.44 |
| ▸ | CASP8 | Q14790 | 14/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20981228 | 0.92 | CASP3 (0.49) | CASP3CASP6CASP8 | |
| SCHEMBL20827575 | 0.84 | CASP3 (0.56) | CASP3CASP6CASP8 | |
| SCHEMBL20981231 | 0.82 | CTSK (0.40) | CASP3CASP6CASP8KDM1ARCOR1 | |
| SCHEMBL20980797 | 0.81 | CASP3 (0.53) | CASP3CASP6CASP8CTSSCTSK | |
| SCHEMBL22404667 | 0.78 | KLK7 (0.47) | CASP3CASP6CASP8 | |
| SCHEMBL25985480 | 0.75 | CASP3 (0.59) | CASP3CASP6CASP8 | |
| SCHEMBL19918338 | 0.75 | CA1 (0.54) | KDM1ARCOR1 | |
| SCHEMBL22390623 | 0.74 | CASP3 (0.60) | CASP3CASP6CASP8 | |
| SCHEMBL22390624 | 0.74 | CASP3 (0.60) | CASP3CASP6CASP8 | |
| SCHEMBL22404745 | 0.73 | KLK7 (0.46) | CASP3CASP6CASP8CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981860-B2 | Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof | CASP1, CASP14, CASP2 | CASP3 7/4885CASP6 9/4885CASP8 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.